In Vitro Studies on Synergism in Combinations of Curcumin and Platinum-based Drugs Against Ovarian Tumour Models

Author

Nurhanan MY., Huq F., Beale P. and Anee Suryani S.
Drug Discovery Centre. Forest Research Institute Malaysia, 52109 Kepong, Selangor
Sydney Medical School, University of Sydney, Lidcombe, NSW 2144, Australia
Tel: 03-6279 7659 E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Language

English

Title

IN VITRO STUDIES ON Synergism IN Combinations OF Curcumin and platinum-based DRUGS Against Ovarian TUMOUR MODELS

Proceeding

Medicinal and Aromatic Plants Seminar (MAPS 2010)

Date

3rd August - 4th August (2010)

Place Held

Forest Research Institute Malaysia(FRIM)

Abstract

Ovarian cancer remains an on-going challenge due to the development of drug resistance and its detection at a late stage (when the cancer is likely to have spread beyond the ovaries). Platinum drugs such as cisplatin, carboplatin and oxaliplatin are used to treat various cancers including the ovarian cancer. New platinum compounds structurally different from cisplatin have been synthesised with the aim of overcoming drug resistance and reducing the toxic side effects. In addition, sequenced combinations of platinums and herbal products are also used to overcome drug resistance. We initiated a study of combining platinums with curcumin, a major compound of Curcuma longa L. or commonly known as turmeric. The study was conducted to determine the best synergistic combination and the effects of combinations on platinum-cell uptake and platinum-DNA binding levels in A2780. A278OcisR and A2780ZD0473R ovarian carcinoma cell lines. The results showed that sequential addition with 4 h gap produced greater synergism. The order of synergism was found to be generally in line with that of cell uptake and platinum-DNA binding.

Keywords

Synergism; anti-proliferative effect; curcumin; platinum; ovarian carcinoma

Session

Poster Abstracts: P17

Topic

Harnessing the Tropical heritage: Recent Advances in R&D and commercialization